Heartbeat clues: could your pulse predict IBD drug success?

NCT ID NCT07475052

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study looks at whether continuous heart rate variability (HRV) monitoring can predict how well patients with inflammatory bowel disease (IBD) respond to biologic therapies like infliximab or vedolizumab. Researchers will track HRV in 100 patients starting treatment and compare those who respond versus those who don't at 14 weeks. The goal is to find a simple, non-invasive way to personalize IBD treatment early on.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which IBD patients will benefit from biologic drugs like infliximab or vedolizumab, avoiding ineffective treatments.
What could go wrong
This is an early observational study with only 100 participants, so results may not apply to all patients. The link between heart rate variability and treatment response is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOLOGICS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Xijing Hospital

    Xi'an, Shaanxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.